Myriad Pharmaceuticals, Inc. Announces the Identification of an IND Candidate for the Treatment of Cancer, Obesity, and Diabetes

SALT LAKE CITY, Oct. 13, 2009 (GLOBE NEWSWIRE) -- Myriad Pharmaceuticals, Inc. (Nasdaq:MYRX) today announced the identification of an Investigational New Drug (IND) candidate targeting a novel molecular target, the protein kinase IKK epsilon.